Scope, Claims, and US Patent Landscape for US Patent 8,999,386 (Extended-Release Chewable Racemic Methylphenidate Tablets)
US Patent 8,999,386 is directed to a 12-hour extended-release chewable tablet for racemic methylphenidate (typically racemic methylphenidate HCl) that uses a uniform solid dispersion combining: (i) a sustained-release component formed from racemic methylphenidate-ion exchange resin complex with a water-insoluble, water-permeable, pH-independent barrier coating (barrier-coated resin complex in a polymeric matrix), plus (ii) two immediate-release fractions: one is slower-onset immediate release from an uncoated methylphenidate-ion exchange resin complex, and the other is faster-onset immediate release from uncomplexed racemic methylphenidate. The patent locks the composition and performance to defined weight fractions and pharmacokinetic (PK) windows under fasted and fed conditions, and also includes divisibility requirements for maintaining both immediate and extended release properties.
What is US Patent 8,999,386 claiming about extended release chewable racemic methylphenidate?
Core concept (Claim 1):
A chewable, uniform solid dispersion containing three pharmacokinetic “release populations” of racemic methylphenidate:
-
Sustained-release fraction (a)
- A racemic methylphenidate-ion exchange resin complex in a polymeric matrix
- The complex is overcoated by a barrier that is water-insoluble, water-permeable, pH-independent
- The barrier provides the sustained release profile over the complex-matrix
-
Slower-onset immediate release fraction (b)
- Immediate release uncoated racemic methylphenidate-ion exchange resin complex
-
Faster-onset immediate release fraction (c)
- Immediate release uncomplexed racemic methylphenidate
Release timing structure:
- (b) has a slower onset of release than (c)
Quantified loading architecture:
- About 50% to about 90% w/w of racemic methylphenidate is from the sustained-release component (a)
- Immediate release together (b) + (c): about 20% to about 40% w/w
PK performance locks (Claim 1):
Under single 40 mg oral dose of racemic methylphenidate HCl in adults, under fasted and fed:
- AUC0-∞ (geometric mean): ~110 to ~140 ng·hr/mL
- Cmax (geometric mean): ~10 to ~15 ng/mL
Divisibility constraint:
- The tablet can be divided into portions that retain therapeutically effective immediate release and 12-hour extended release profile.
How dependent claims narrow the barrier and immediate-release fractions
The claim set then tightens barrier material options, resin complex composition ratios, tablet mechanical properties, and explicit formulation exemplars.
Which active form of racemic methylphenidate is covered and how specific are the compositions?
Racemic salt coverage:
- Claim 18 and Claim 29 specify the active drug is racemic methylphenidate HCl.
Resin complex vs uncomplexed methylphenidate are both required:
- The sustained-release fraction uses a resin complex under a barrier coating
- The two immediate-release fractions split racemic methylphenidate into:
- uncoated resin complex (slower onset)
- uncomplexed methylphenidate (faster onset)
What is the sustained-release resin complex barrier?
Claim 11 defines a pH-independent barrier coating “selected from”:
- (a) cured, water-permeable, non-ionic, pH-independent barrier coating comprising:
- polyvinylacetate
- stabilizer
- plasticizer
- applied as an aqueous dispersion
- (b) ionic, pH-independent acrylic based coating comprising polymer/copolymer of:
- ethyl acrylate + methyl methacrylate with trimethylammonioethyl methacrylate chloride in copolymer
- applied as an aqueous dispersion
- (c) solvent-based ethylcellulose coating, optionally with a plasticizer
Claims 12-13 then narrow to specific embodiments.
What barrier coating compositions and mechanical properties are explicitly claimed?
Barrier performance-defined as “water-insoluble, water-permeable, pH-independent”
Claim 11 sets the barrier characterization; dependent claims define specific barrier formulations.
Polyvinylacetate barrier embodiment (Claim 12)
Barrier coating over the resin complex-matrix:
- 70% to 90% w/w polyvinylacetate
- 2% to 10% w/w plasticizer
- plus stabilizer
Acrylic barrier embodiment (Claim 13)
Barrier coating is an ionic acrylic blend of two poly(amino-methacrylate-chloride) copolymers:
- Copolymer (i): 1:2:0.1 ratio
- Copolymer (ii): 1:2:0.2 ratio
(ethyl acrylate : methyl methacrylate : trimethylammonioethyl methacrylate chloride)
Tablet hardness (Claim 10; also Claim 25)
Optional non-functional outer top coating (Claim 14)
- Includes an outer “non-functional” top layer, indicating the enforceable innovation is in the internal dispersion and barrier-coated resin complex, not in taste/appearance layers.
What are the key weight-fraction ranges that define scope and infringement risk?
Sustained-release vs immediate-release loading
Claim 1 (top-level):
- Sustained-release fraction (a): ~50% to ~90% w/w
- Immediate release (b) + (c): ~20% to ~40% w/w
Claim 4 narrows sustained-release to:
Claim 5 narrows immediate-release total to:
- ~20% to ~40% w/w (same range, reinforced)
Split of immediate release between resin complex vs uncomplexed drug
Claim 6:
- Immediate-release resin complex (b): ~5% to ~35% w/w
Claim 7:
- Uncomplexed methylphenidate (c): ~5% to ~35% w/w
Claim 9:
- Ratio (b):(c) is about 3:1 based on total immediate-release components.
Claim 8 gives one specific mapping:
- (b) provides about 15% w/w
- (c) provides about 15% w/w
This mapping implies a total immediate-release share of ~30% and sustained-release share of ~70% for that dependent setup, but Claim 1’s broader ranges remain controlling in independent claim scope.
How do the PK limitations function: what are the “performance claims” exactly?
US 8,999,386 includes PK windows that constrain the formulation scope beyond composition alone.
Claim 1 PK window (geometric means; fasted + fed)
- AUC0-∞: ~110 to ~140 ng·hr/mL
- Cmax: ~10 to ~15 ng/mL
- Dose: 40 mg racemic methylphenidate HCl; adults; single dose; chewable extended release.
Claim 2 additional PK metric (Tmax and AUC0-3)
- Tmax ~4 to 5.25 hours
- AUC0-3 ~18 ng·hr/mL
(“under fasted and fed conditions”)
Claim 3 additional fasted/fed breakouts
- Fasted: AUC0-∞ ~113
- Fed: AUC0-∞ ~138
- Cmax: ~12 to ~13 ng/mL (fasted and fed)
- Tmax: 4 to 4.5 hours (arithmetic mean)
- T1/2: 5 to 7 hours (arithmetic mean)
Claim 19 (parallel PK lock for the “rapid onset” variant)
Claim 19 repeats the PK lock with single mean geometric values, plus a different polymeric matrix description (polyvinylpyrrolidone matrix), and includes “rapid on-set” language.
How does claim 19 change the barrier and matrix while keeping the same overall performance concept?
Claim 19 is a second independent-style claim with the same architectural tri-component release system and PK windows.
Key changes:
- Sustained-release component (a) includes:
- ~25% to ~40% w/w of cured barrier-coated racemic methylphenidate-barrier ion exchange resin complex
- barrier coating includes polyvinylacetate, stabilizer, plasticizer
- sustained component is embedded in a polyvinylpyrrolidone matrix
- Immediate release components include:
- first immediate release (b): immediate release racemic methylphenidate-ion exchange resin complex
- second immediate release (c): racemic methylphenidate active component
- Maintains:
- (b) slower onset than (c)
- 50% to 90% sustained-release fraction
- chewable divisibility retaining 12-hour profile
- PK: AUC0-∞ ~110 to ~140
- Cmax ~10 to ~15
So Claim 19 narrows to a particular sustained-release matrix choice (PVP) and a specific PVAc barrier formulation embodiment.
What does the “dividable chewable” limitation mean for enforcement?
Claim 1 requires that the tablet is:
- capable of being divided
- and divided portions retain a therapeutically effective immediate release and 12-hour extended release profile
That is not a mere structural chewability claim. It creates an enforceable functional requirement tied to maintaining release kinetics in split halves or portions, which can matter in:
- manufacture of scored or fractureable tablets
- uniformity of dispersion across the tablet face
- consistency of barrier-coated resin distribution
What are the fully specified formulation ranges (claims 15–17 and 16–17) and what is claimed about excipient choices?
These dependent claims enumerate a quantitative exemplar composition for the pre-coating tablet mass.
Claim 15: broad excipient ranges tied to tablet fraction architecture
- Coated resin complex (sustained): 15% to 20% w/w
- Uncoated resin complex (slower onset): 1.5% to 5% w/w
- Uncomplexed racemic methylphenidate (faster onset): 0.5% to 1% w/w
- Fillers: 45% to 85% w/w
- Disintegrant(s): 5% to 10% w/w
- Buffering agent: 0.1% to 10% w/w
- Sweeteners: 1% to 3% w/w
- Flavoring agent: 0.1% to 3% w/w
- Lubricants: 0.2% to 3% w/w
- Glidants: 0.01% to 1% w/w
- Colorants: 0.01% to 0.5% w/w
Claim 16: narrower numerical ranges
- Coated resin complex (sustained): 16% to 18% w/w
- Uncoated resin complex: 2% to 3% w/w
- Uncomplexed methylphenidate: 0.5% to 0.8% w/w
- Fillers: 50% to 70% w/w
- Disintegrant: 7% to 8% w/w
- Buffer: 0.5% to 1.5% w/w
- Sweeteners: 1% to 2% w/w
- Flavor: 0.1% to 1% w/w
- Lubricants: 1.5% to 3% w/w
- Glidants: 0.01% to 1% w/w
- Colorants: 0.02% to 0.08% w/w
Claim 17: explicit excipient identity list (functional reinforcement)
- Fillers: mannitol, xanthan gum, microcrystalline cellulose, guar gum, mixtures
- Disintegrant: crospovidone
- Lubricants: talc, magnesium stearate, mixtures
- Buffer: citric acid and salts
Interpretive impact for landscape: claims 15–17 create enforceable “fallback positions” that are easier to map in an accused product if excipient selections match, while independent claim 1 is broader.
What method claim is included and how does it broaden enforcement beyond product-only?
Claim 30:
- A method for providing a subject with a therapeutically effective amount of racemic methylphenidate over at least 12 hours
- via delivering a single extended release chewable tablet according to claim 1
This supports:
- infringement theories for use instructions and physician/patient administration when the product is used as claimed
- parallel attack to product claims if clinical instructions track the patented use window
How does this patent likely relate to known methylphenidate ER chewable architectures (and what does that imply for design-around)?
This claim set is specifically built around:
- ion-exchange resin complex formation (coated and uncoated forms)
- barrier-coated, pH-independent, water-insoluble/water-permeable coatings
- two immediate-release fractions with distinct onset rates by shifting between:
- resin complex vs uncomplexed drug
Design-around pressure points
A future competitor seeking to avoid literal infringement would typically move at least one of these anchors:
- remove the barrier-coated pH-independent, water-insoluble/water-permeable requirement
- replace ion-exchange resin complex with a different sustained-release mechanism
- eliminate the split immediate release system that differentiates faster uncomplexed drug from slower resin complex
- shift PK performance outside the locked ranges, though that tends to require new clinical data and product redesign
- change tablet divisibility behavior if it is a claimed functional requirement
What is the US patent estate scope around US 8,999,386 and how is it typically defended?
Without the full prosecution history and family listings for US 8,999,386, a complete landscape mapping across:
- related US continuations
- PCT family members
- expiring patents in the methylphenidate ER chewable space
- Orange Book listings for specific NDA products
cannot be produced from the claim text alone.
What can be concluded from claim drafting is the patent is structured for layered enforcement:
- Independent claim 1: broad barrier selection (PVAc, acrylic, ethylcellulose), broad loading ranges, and PK windows.
- Independent claim 19: PVAc barrier plus PVP matrix embodiment, “rapid onset” labeling, and the same PK windows.
- Dependent claims 10–17: mechanical property, barrier composition percentages, and specific excipient lists provide narrow claim fallbacks.
- Method claim 30: extends enforcement into administration.
Key Takeaways
- US 8,999,386 claims a 12-hour extended-release chewable made as a uniform solid dispersion with three methylphenidate populations: sustained barrier-coated resin complex, slower-onset uncoated resin complex, and faster-onset uncomplexed methylphenidate.
- Scope is defined by weight-fraction bands and PK performance windows for a 40 mg racemic methylphenidate HCl dose under fasted and fed conditions.
- The barrier coating is a central claim element: water-insoluble, water-permeable, pH-independent, with explicit PVAc and acrylic embodiments and fallback ethylcellulose language.
- Dependent claims lock in tablet hardness, divisibility retaining release, and detailed excipient identities/ranges, creating multiple levels of enforceability.
- A method-of-use claim targets administration delivering racemic methylphenidate for at least 12 hours using a tablet meeting claim 1.
FAQs
1) What makes infringement of US 8,999,386 difficult: composition or PK?
Both. The claims combine a specific three-fraction release architecture with locked PK ranges (AUC0-∞ and Cmax for claim 1; additional Tmax/AUC0-3/T1/2 metrics in dependent claims).
2) Does the patent require pH-independent barrier coating, and is that satisfied by every water-permeable coating?
No. The barrier must be characterized as water-insoluble, water-permeable, and pH-independent, with dependent claims specifying particular polymer systems and loading percentages.
3) Is ion-exchange resin complex required for all methylphenidate fractions?
No. The patent requires resin complex for:
- the sustained-release fraction (barrier-coated)
- the slower-onset immediate-release fraction (uncoated)
But it also requires a faster-onset immediate-release fraction that is uncomplexed racemic methylphenidate.
4) Can a manufacturer avoid the claim by changing tablet hardness or excipients?
Changing excipients/hardness may avoid narrower dependent claims (10, 15–17) but not necessarily independent claim 1, which does not require those specific excipient identities or hardness ranges.
5) Is “rapid on-set” protection separate from the main 12-hour extended release claim?
Claim 19 is an additional independent claim framed with “rapid on-set,” but it keeps the same overall tri-component dispersion architecture and the same PK window structure, with further narrowing to PVAc barrier plus PVP matrix.
References
- US Patent 8,999,386. “Extended release chewable tablet comprising barrier coated racemic methylphenidate-ion exchange resin complex and immediate release fractions; and methods of use.” (Claim text provided in the prompt).
